Related Experiment Video
Updated: Jul 18, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice
Shin-ichiro Nakagawa1, Takuya Umehara, Chiho Matsuda
1Department of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8613, Japan.
Insights
Inhibiting heat shock protein 90 (Hsp90) effectively suppresses hepatitis C virus (HCV) replication. Targeting Hsp90 offers a promising new therapeutic strategy for treating HCV infections.
Area of Science:
- Hepatology
- Virology
- Molecular Biology
Background:
- Persistent hepatitis C virus (HCV) infection leads to severe liver diseases, including cirrhosis and cancer.
- Current treatments for HCV can be limited by efficacy and side effects.
Purpose of the Study:
- To investigate the role of heat shock protein 90 (Hsp90) in HCV replication.
- To evaluate the therapeutic potential of Hsp90 inhibition for HCV infection.
Main Methods:
- Utilized HCV replicon cell systems to assess the impact of Hsp90 inhibitors and siRNA-mediated knockdown on viral replication.
- Examined the effect of Hsp90 inhibition in HCV-infected chimeric mice with humanized livers.
- Compared the efficacy of Hsp90 inhibitor combined with pegylated interferon (PEG-IFN) against PEG-IFN monotherapy.
Main Results:
- Hsp90 inhibitors and Hsp90 knockdown significantly reduced HCV genome replication in cell-based assays.
- The suppressive effect of Hsp90 inhibitors on HCV replication was reversed by Hsp90 expression.
- Combination therapy with an Hsp90 inhibitor and PEG-IFN demonstrated superior reduction of serum HCV RNA levels compared to PEG-IFN alone in vivo.
Conclusions:
- Heat shock protein 90 plays a crucial role in supporting HCV replication.
- Inhibition of Hsp90 presents a novel and effective therapeutic strategy for managing HCV infections.
- Combined Hsp90 inhibition and PEG-IFN therapy may offer an enhanced treatment approach for hepatitis C.
Abstract:
Persistent infection with hepatitis C virus (HCV) is a major cause of liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Here we report that inhibition of heat shock protein 90 (Hsp90) is highly effective in suppressing HCV genome replication. In HCV replicon cells, HCV replication was reduced by Hsp90 inhibitors and by knockdown of endogenous Hsp90 expression mediated by small-interfering RNA (siRNA). The suppression of HCV replication by an Hsp90 inhibitor was prevented by transfection with Hsp90 expression vector. We also tested the anti-HCV effect of Hsp90 inhibition in HCV-infected chimeric mice with humanized liver. Combined administration of an Hsp90 inhibitor and polyethylene glycol-conjugated interferon (PEG-IFN) was more effective in reducing HCV genome RNA levels in serum than was PEG-IFN monotherapy. These results suggest that inhibition of Hsp90 could provide a new therapeutic approach to HCV infection.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly
Hepatitis

